• 1
    Wauquier A, Zhou S. Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res 1996;24: 737.
  • 2
    White HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 1997;38(suppl 1):S917.
  • 3
    Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures: Topiramate YTC Study Group. Neurology 1999;52: 13307.
  • 4
    Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000;41: 97780.
  • 5
    Shank RP, Gardocki JF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41(suppl 1):S39.
  • 6
    McLean MJ, Bukhari AA, Wamil AW. Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia 2000;41(suppl 1):S214.
  • 7
    Wu SP, Tsai JJ, Gean PW. Frequency-dependent inhibition of neuronal activity by topiramate in rat hippocampal slices. Br J Pharmacol 1998;125: 82632.
  • 8
    Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett 1997;231: 1236.
  • 9
    Brown SD, Wolf HH, Swinyard EA, et al. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia 1993;34(suppl 2):1223.
  • 10
    White HS, Brown SD, Woodhead JH, et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997;28: 16779.
  • 11
    Gibbs JW III, Sombati S, DeLorenzo RJ, et al. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000;41(suppl 1):S106.
  • 12
    White HS, Brown SD, Woodhead JH, et al. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000;41(suppl 1):S1720.
  • 13
    Zhang X, Velumian AA, Jones OT, et al. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000;41(suppl 1):S5260.
  • 14
    Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia 1994;35: 45060.
  • 15
    Kuzniecky R, Hetherington H, Ho S, et al. Topiramate increases cerebral GABA in healthy humans. Neurology 1998;51: 6279.
  • 16
    Kuzniecky R, Ho S, Pan J, et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 2002;58: 36872.
  • 17
    Petroff OA, Hyder F, Rothman DL, et al. Topiramate rapidly raises brain GABA in epilepsy patients. Epilepsia 2001;42: 5438.
  • 18
    Manganotti P, Bongiovanni LG, Zanette G, et al. Cortical excitability in patients after loading doses of lamotrigine: a study with magnetic brain stimulation. Epilepsia 1999;40: 31621.
  • 19
    Ziemann U, Rothwell JC, Ridding MC. Interaction between intracortical inhibition and facilitation in human motor cortex. J Physiol 1996;496: 87381.
  • 20
    Siebner HR, Dressnandt J, Auer C, et al. Continuous intrathecal baclofen infusions induced a marked increase of the transcranially evoked silent period in a patient with generalized dystonia. Muscle Nerve 1998;21: 120912.
  • 21
    Manganotti P, Bongiovanni LG, Zanette G, et al. Early and late intracortical inhibition in juvenile myoclonic epilepsy. Epilepsia 2000;41: 112938.
  • 22
    Schwenkreis P, Liepert J, Witscher K, et al. Riluzole suppresses motor cortex facilitation in correlation to its plasma level: a study using transcranial magnetic stimulation. Exp Brain Res 2000;135: 2939.
  • 23
    Ziemann U, Chen R, Cohen LG, et al. Dextromethorphan decreases the excitability of the human motor cortex. Neurology 1998;51: 13204.
  • 24
    Kujirai T, Caramia MD, Rothwell JC, et al. Corticocortical inhibition in human motor cortex. J Physiol 1993;471: 50119.
  • 25
    Mills KR, Boniface SJ, Schubert M. Magnetic brain stimulation with a double coil: the importance of coil orientation. Electroencephalogr Clin Neurophysiol 1992;85: 1721.
  • 26
    Werhahn KJ, Kunesch E, Noachtar S, et al. Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J Physiol 1999;517: 5917.
  • 27
    Tergau F, Wanschura V, Canelo M, et al. Complete suppression of voluntary motor drive during the silent period after transcranial magnetic stimulation. Exp Brain Res 1999;124: 44754.
  • 28
    Wilson SA, Lockwood RJ, Thickbroom GW, et al. The muscle silent period following transcranial magnetic cortical stimulation. J Neurol Sci 1993;114: 21622.
  • 29
    Garvey MA, Ziemann U, Becker DA, et al. New graphical method to measure silent periods evoked by transcranial magnetic stimulation. Clin Neurophysiol 2001;112: 145160.
  • 30
    Ben-Menachem E. Potential antiepileptic drugs. In: LevyRH, ed. Topiramate: antiepileptic drugs. New York: Raven Press, 1995: 106370.
  • 31
    Walker MC, Sander JW. Topiramate: a new antiepileptic drug for refractory epilepsy. Seizure 1996;5: 199203.
  • 32
    Christensen J, Hojskov CS, Dam M, et al. Plasma concentration of topiramate correlates with cerebrospinal fluid concentration. Ther Drug Monit 2001;23: 52935.
  • 33
    Ziemann U, Lonnecker S, Steinhoff BJ, et al. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol 1996;40: 36778.
  • 34
    Ziemann U, Lonnecker S, Steinhoff BJ, et al. The effect of lorazepam on the motor cortical excitability in man. Exp Brain Res 1996;109: 12735.
  • 35
    Schwenkreis P, Witscher K, Janssen F, et al. Influence of the N-methyl-d-aspartate antagonist memantine on human motor cortex excitability. Neurosci Lett 1999;270: 137-40.
  • 36
    Hess CW, Mills KR, Murray NM, et al. Excitability of the human motor cortex is enhanced during REM sleep. Neurosci Lett 1987;82: 4752.
  • 37
    Chen R, Samii A, Canos M, et al. Effects of phenytoin on cortical excitability in humans. Neurology 1997;49: 8813.
  • 38
    Hallett M. Transcranial magnetic stimulation: negative effects. Adv Neurol 1995;67: 10713.
  • 39
    Roick H, Von Giesen HJ, Benecke R. On the origin of the postexcitatory inhibition seen after transcranial magnetic brain stimulation in awake human subjects. Exp Brain Res 1993;94: 48998.
  • 40
    Sills GJ, Leach JP, Kilpatrick WS, et al. Concentration-effect studies with topiramate on selected enzymes and intermediates of the GABA shunt. Epilepsia 2000;41: 304.
  • 41
    Berkovic SF. Aggravation of generalized epilepsies. Epilepsia 1998;39(suppl 3):S114.
  • 42
    Hosford DA, Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 1997;38: 40814.
  • 43
    Wheless JW. Use of topiramate in childhood generalized seizure disorders. J Child Neurol 2000;15(suppl 1):S713.
  • 44
    Knake S, Hamer HM, Schomburg U, et al. Tiagabine-induced absence status in idiopathic generalized epilepsy. Seizure 1999;8: 3147.
  • 45
    Eckardt KM, Steinhoff BJ. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment. Epilepsia 1998;39: 6714.
  • 46
    Boroojerdi B, Kopylev L, Battaglia F, et al. Reproducibility of intracortical inhibition and facilitation using the paired-pulse paradigm. Muscle Nerve 2000;23: 15947.